Myzomib 2 mg Injection
  1. Home
  2. Pharma Products
  3. Mylan Pharmaceuticals Pvt Ltd
  4. Myzomib 2 mg Injection

Myzomib 2 mg Injection

Myzomib 2 mg Injection contains bortezomib 2 mg, an anticancer medicine belonging to the proteasome inhibitor group. It is used in the treatment of multiple myeloma and mantle-cell lymphoma. The injection is administered by a qualified healthcare professional under medical supervision.

BUY NOW

Category

Bortezomib works by blocking proteasomes, which interferes with protein breakdown and can lead to the death of certain cancer cells. It may be used alone or in combination with other medicines according to the prescribed oncology treatment protocol. Blood counts and other clinical parameters are generally monitored during therapy because treatment can cause thrombocytopenia, anemia, peripheral neuropathy, and gastrointestinal effects. The dose and treatment schedule are individualized according to the patient’s condition, response to therapy, and clinical protocol.

Technical Specification

Specification Details
Active Ingredient Bortezomib
Strength 2 mg
Dosage Form Powder for Injection
Route of Administration Intravenous or Subcutaneous
Pack Size 1 Vial
Marketer Mylan Pharmaceuticals Pvt Ltd – A Viatris Company

Product Also Known As

Myzomib 2 mg Injection, Myzomib 2mg Injection, Myzomib 2 mg Vial, Bortezomib 2 mg Injection, Bortezomib 2mg Injection, Bortezomib 2 mg Vial, Bortezomib Anticancer Injection